GB9226832D0 - Pharmaceutical preparations for the treatment of psoriasis - Google Patents
Pharmaceutical preparations for the treatment of psoriasisInfo
- Publication number
- GB9226832D0 GB9226832D0 GB929226832A GB9226832A GB9226832D0 GB 9226832 D0 GB9226832 D0 GB 9226832D0 GB 929226832 A GB929226832 A GB 929226832A GB 9226832 A GB9226832 A GB 9226832A GB 9226832 D0 GB9226832 D0 GB 9226832D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- psoriasis
- treatment
- pharmaceutical preparations
- preparations
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9226832A GB2273873A (en) | 1992-12-23 | 1992-12-23 | Treatment of psoriasis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9226832A GB2273873A (en) | 1992-12-23 | 1992-12-23 | Treatment of psoriasis |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9226832D0 true GB9226832D0 (en) | 1993-02-17 |
GB2273873A GB2273873A (en) | 1994-07-06 |
Family
ID=10727120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9226832A Withdrawn GB2273873A (en) | 1992-12-23 | 1992-12-23 | Treatment of psoriasis |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2273873A (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US5847007A (en) * | 1993-05-13 | 1998-12-08 | Neorx Corporation | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5633274A (en) * | 1993-02-18 | 1997-05-27 | President And Fellows Of Harvard College | Cancer treatments |
US5512591A (en) * | 1993-02-18 | 1996-04-30 | President And Fellows Of Harvard College | Treatments for diseases characterized by neovascularization |
DE4407742C1 (en) * | 1994-03-08 | 1995-06-22 | Hexal Pharma Gmbh | Transdermal patch for treating tumours |
US5556871A (en) * | 1995-04-24 | 1996-09-17 | President & Fellows Of Harvard College | Method for treating epithelial precancerous lesions with topical inidazoles |
AU6277396A (en) | 1995-06-07 | 1996-12-30 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
CO5271709A1 (en) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | COMPOSITIONS AND PROCEDURES FOR THE AND TREATMENT OF AFFECTIONS RESPONDING TO STROGENS |
EP1345618B1 (en) * | 2000-12-28 | 2005-03-23 | Switch Biotech Aktiengesellschaft | Chlorzoxazone for the treatment of psoriasis |
GB0710899D0 (en) * | 2007-06-07 | 2007-07-18 | Syntopix Ltd | Formulations |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3114824A1 (en) * | 1980-05-07 | 1982-04-08 | Gerhard Prof.Dr.med. 8500 Nürnberg Weber | "USE OF A MEDICINE FOR THE TREATMENT OF PSORIASIS (psoriasis)" |
-
1992
- 1992-12-23 GB GB9226832A patent/GB2273873A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
GB2273873A (en) | 1994-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5281607B1 (en) | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases | |
GB2188844B (en) | Pharmaceutical composition for the treatment of psoriasis | |
HU9300536D0 (en) | Compounds of medical effect | |
AU4048295A (en) | Peptide medicaments for the treatment of disease | |
GB9226832D0 (en) | Pharmaceutical preparations for the treatment of psoriasis | |
IL101410A0 (en) | Formulation for the treatment of cancer | |
EP0577023A3 (en) | Angiotensin-ii receptor-antagonists for the treatment of arrhythmices | |
AU2806692A (en) | Medicament for the treatment of anxiety | |
AU4220193A (en) | Deazaaminopterins for treatment of inflammation | |
GB9103278D0 (en) | Drug for the treatment of dermatitis | |
AU4081393A (en) | Medicaments for the treatment of anxiety | |
IL93242A0 (en) | Pharmaceutical preparation for the treatment of tonsillitis | |
ZA932450B (en) | Drugs for the treatment of diabetes | |
HU9402816D0 (en) | Medicament for the treatment of airways inflammation and airways hyperresponsiveness | |
PL308307A1 (en) | 3-substituted 2-oxyindolo-1-carboxylamide pharmaceutical preparations | |
IL99236A0 (en) | Pharmaceutical composition for the topical treatment of psoriasis | |
IL105690A0 (en) | Pharmaceutical compositions for the treatment of arrhythmia | |
NZ255753A (en) | Use of substituted azaspiranes for psoriasis treatment | |
AU4825993A (en) | New compounds for use in the treatment of cancer | |
GB9201193D0 (en) | Treatment of liquids | |
AU4119993A (en) | Heteroaroyl-10-deazaaminopterins for treatment of inflammation | |
GB2266241B (en) | Treatment of pastures | |
HU9200294D0 (en) | Process for the production of medical preparations | |
HU913310D0 (en) | Process for the production of medical preparations for treating psoreasis | |
GB9413939D0 (en) | Pharmaceutical composition for the treatment of chronic skin ulcers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |